Tag

Moderna

All articles tagged with #moderna

science15 days ago•7 min saved

Moderna and Korean Partners Target Broad Hantavirus Vaccine With mRNA Tech

Moderna and Korea University’s Vaccine Innovation Center have been collaborating since 2023 to create an mRNA hantavirus vaccine; early preclinical results in mice (reported in 2025) show protection, but the vaccine is not yet in humans and faces funding, regulatory, and multi-strain coverage challenges, as there is currently no licensed hantavirus vaccine and the effort aims for a broad-spectrum solution in line with pandemic‑preparedness goals.

via WIRED|

#hantavirus #moderna #mrna

markets15 days ago•3 min saved

Hantavirus Outbreak Triggers Cautious Biotech Stock Rally

Biotech stocks such as Moderna, Inovio, and Novavax rose on hantavirus outbreak headlines, but analysts cautioned the moves are sentiment-driven with limited revenue potential; Moderna noted ongoing preclinical hantavirus work with USAMRIID, while the WHO said the public health risk remains low and the incident appears contained.

via CNBC|

#biotech-stocks #hantavirus #inovio

technology18 days ago•1 min saved

Moderna Advances Early Hantavirus Vaccine Research Ahead of Cruise-Outbreak Scrutiny

Moderna says it’s pursuing early-stage hantavirus vaccine work with the US Army Medical Research Institute of Infectious Diseases and Korea University’s Vaccine Innovation Center, begun before the Hondius cruise-ship outbreak, as public health officials say the immediate risk remains limited while the company develops countermeasures.

via The Boston Globe|

#cruise-outbreak #hantavirus #infectious-disease

market-news18 days ago•15 min saved

Moderna Stock Pops 14% on Early Hantavirus Vaccine Work

Moderna’s shares jumped about 14% after news of early hantavirus vaccine research with the U.S. Army and Korea University, though executives say the work is in its infancy and not close to a vaccine. Experts note funding has been limited because hantavirus outbreaks are rare, suggesting a vaccine could be years or even a decade away. Wall Street shows a Hold consensus on MRNA with a $41.75 target implying potential downside, so the stock move reflects long‑term research interest rather than near‑term product prospects.

via TipRanks|

#hantavirus #market-news #moderna

business18 days ago•78 min saved

Moderna shares jump as hantavirus outbreak stirs vaccine optimism

Moderna, Inc. stock rose about 12% on news of a hantavirus outbreak, signaling investor optimism for potential vaccine demand; the move pushed Moderna’s share price toward the low $50s, reflecting broader market enthusiasm for vaccine developers amid outbreak concerns.

via Yahoo Finance|

#business #hantavirus #moderna

health20 days ago•5 min saved

mRNA flu shot beats standard vaccine in major trial, FDA decision looming

In a Phase 3 trial of more than 40,000 adults aged 50+, Moderna's mRNA influenza vaccine reduced illness to about 2.0% vs 2.8% for standard vaccines (roughly 27% more effective), with similar improvement in adults 65+. Side effects were mild. The FDA decision on licensure is expected by Aug. 5, as Moderna pursues approval; no mRNA flu vaccine is approved anywhere yet.

via NBC News|

#fda #flu-vaccine #health

markets2 months ago•2 min saved

BoA Data Unmasks Hedge Funds’ Top 20 Short Targets

Bank of America’s latest data rank the 20 stocks hedge funds are most shorted; Moderna (MRNA) leads with about 18.3% of its float short, followed by names like SMCI, CHTR, APA, HPQ, BBY, WDC and MGM, illustrating broad bets against a wide mix of equities as the S&P 500 sits roughly 3% lower year-to-date.

via Seeking Alpha|

#bofa-securities #hedge-funds #markets

health2 months ago•3 min saved

FDA vaccine chief Vinay Prasad exits amid regulatory clashes

FDA vaccine chief Dr. Vinay Prasad is leaving the agency at the end of April to return to UCSF, marking a second departure in under a year amid ongoing controversies over vaccine and rare-disease drug reviews, including disputes with Moderna over an mRNA flu vaccine and with UniQure on a Huntington's disease gene therapy.

via CBS News|

#fda #health #huntingtons-disease

biotechnology2 months ago•2 min saved

Moderna Roivant patent deal caps biotech patent fight at $2.25B

Moderna will pay Roivant up to $2.25 billion to settle patent infringement claims over its Covid-19 vaccine, while The Readout highlights Prime Medicine’s gene-therapy work and FDA warnings to telehealth firms over compounded GLP-1s.

via statnews.com|

#biotechnology #gene-therapy #moderna

politics2 months ago•1 min saved

Kennedy’s Vaccine Pivot Triggers Backlash Within His Base

Health Secretary Robert F. Kennedy Jr.’s push to overhaul the vaccine program has provoked anger among his anti-vaccine allies as regulators briefly dropped—and then revived—the review of Moderna’s mRNA flu shot, fueling claims he’s betrayed the movement by leaving much of the vaccine apparatus intact while shifting focus to other causes like real-food policy. Veteran supporters, including Derrick Wynne who opposed vaccines, say Kennedy used the movement for traction, underscoring a widening rift ahead of the midterms.

via The New York Times|

#anti-vaccine-movement #health-policy #moderna

health3 months ago•14 min saved

Moderna's mRNA flu shot moves to FDA review after dispute resolution

Moderna says the FDA will review its experimental mRNA-based flu vaccine after resolving a public dispute, signaling movement toward potential regulatory consideration of the shot.

via AP News|

#fda #flu-vaccine #health

politics3 months ago•6 min saved

White House pressure prompts FDA to reopen Moderna flu shot review

The FDA reversed its initial refusal to accept Moderna’s seasonal flu vaccine filing after a White House meeting in which President Trump pressed the agency, with Moderna submitting an amended filing and the FDA agreeing to review it via a Type A meeting. The agency accepted the application for full approval for adults 50–64 and accelerated approval for 65+, with a post‑marketing study to address age-related concerns, and a target decision date of August 5, 2026.

via Politico|

#fda #moderna #politics

health3 months ago•18 min saved

FDA to review Moderna’s mRNA flu vaccine after new study plan

The FDA reversed its earlier decision and will review Moderna’s first mRNA-based influenza vaccine after Moderna agreed to conduct additional studies in older adults under a revised review process.

via The Washington Post|

#clinical-trials #fda #flu

health3 months ago•4 min saved

FDA reopens review of Moderna’s mRNA flu shot ahead of fall rollout

The FDA has agreed to review Moderna’s experimental mRNA flu vaccine after previously declining to file, with a decision due by August 5; Moderna seeks full approval for adults 50–64 and accelerated approval for 65+, contingent on a post‑marketing study, amid broader regulatory shifts and debate over vaccine oversight.

via CNBC|

#fda #flu-vaccine #health

health3 months ago•1 min saved

FDA Signals Review for Moderna's Next-Gen Flu Vaccine

The FDA has reversed its earlier stance and agreed to review Moderna’s updated mRNA flu vaccine, with plans for full approval in adults 50–64 and accelerated approval for those 65 and older, plus a post-marketing study in older adults. A decision is expected by August 5, and Moderna shares rose on the news.

via NBC News|

#approval-timeline #fda #health